In the search for next generation therapies, we are seeing a number of trends emerge in the pharma and healthcare sectors; a shift towards digitalisation, embracing artificial intelligence (AI) and a move away from the one-size fits all approach towards personalised, individualised medicines.
These trends are redefining the healthcare industry by promoting continuous innovation and improving patient outcomes. Digitalisation is streamlining research and development processes, making it easier to manage and analyse large datasets, leading to more accurate outcomes in research and development in the healthcare industry. The adoption of artificial intelligence is enabling more accurate and efficient drug discovery, as well as the development of tailored treatment plans based on individual patient data. The move towards personalised medicine is transforming the traditional healthcare model, allowing for more precise and effective treatments that cater to the unique needs of each patient.
Alongside these opportunities, there are significant challenges. Companies must contend with a range of evolving and increasingly complex legal and regulatory requirements. These include navigating divergent clinical trial protocols across jurisdictions, establishing compliant manufacturing and distribution frameworks within the EU and internationally, and addressing the legal implications of next-generation therapies. The deployment of these advanced technologies frequently involves the large-scale processing of special category data, giving rise to signification data protection considerations and compliance obligations under the General Data Protection Regulation (GDPR) and Ireland's Data Protection Act 2018. In parallel, the EU Artificial Intelligence Act introduces an additional layer of regulations by classifying many medical AI tools as high-risk, thereby imposing additional requirements relating to transparency, human oversight, and data governance. This compounds the already complex regulatory landscape confronting the life sciences and healthcare sectors as they navigate the path between fostering innovation and ensuring regulatory compliance.
Despite the many challenges posed by the evolving regulatory and operational landscape, the pharma and healthcare sectors have continued to attract significant activity in the first quarter of 2025. The level of activity in these sectors can be evidenced by two of the most notable deals so far this year:
- DCC plc's sale of its healthcare division to Investindustrial, a transaction valued at over €1 billion; and
- Mallinckrodt plc, headquartered in Dublin, entering into a definitive agreement to acquire Endo Inc
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
